kidney cancer immunotherapy: pd-1 pathway clinical trials
Published 9 years ago • 477 plays • Length 16:48Download video MP4
Download video MP3
Similar videos
-
11:02
kidney cancer immunotherapy: ctla-4 & vaccine clinical trials
-
3:16
what is pd1 and pdl1 in kidney cancer?
-
1:58
immunotherapy for kidney cancer patients in the front-line setting: coming soon?
-
18:46
kidney cancer immunotherapy: reasons for cautious optimism
-
3:48
the promise of pd1 inhibitors in kidney cancer
-
3:12
immunotherapy treatments for kidney cancer
-
5:47
immunotherapy for metastatic kidney cancer shows increased survival
-
1:17:43
kcrs24 session six: immunotherapy advances in kidney cancer | kidneycan
-
9:52
kidney cancer immunotherapy q&a
-
2:22
are there pd1 biomarkers in kidney cancer?
-
7:41
gracecast-113_lung-cancer_asco 2012 lc highlights: dr. neal on anti-pd-1 immunotherapy for nsclc
-
23:37
gracecast-103_lung-cancer_immunotherapy: yervoy, anti-pd-1, reolysin, talactoferrin by dr. brahmer
-
3:29
are there clinically significant distinctions between pd-1 and pd-l1?
-
14:53
why is immunotherapy more effective in some cancers than others? - part 2
-
19:05
what we know about immunotherapy treatments for lung cancer
-
6:52
combination chemotherapy and immunotherapy for patients with high pd-l1 nsclc - 2022 program: lcvl
-
12:04
currently enrolling clinical trials of single agent immunotherapies for patients with lung cancer
-
35:07
the current role of immunotherapy in the treatment of patients with cancer